Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
71288-0146-50 71288-0146 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Dec. 13, 2022 In Use
71288-0147-50 71288-0147 Pemetrexed disodium Pemetrexed 750.0 mg/30mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Dec. 13, 2022 In Use
71288-0148-51 71288-0148 Pemetrexed disodium Pemetrexed 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Dec. 13, 2022 In Use
00378-3097-85 00378-3097 everolimus everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 15, 2022 In Use
63539-0688-03 63539-0688 palbociclib Ibrance 125.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
00078-0651-06 00078-0651 Panobinostat Farydak 15.0 mg/1 Chemotherapy Enzyme Inhibitor HDAC Oral Feb. 23, 2015 Dec. 31, 2022 No Longer Used
00078-0652-06 00078-0652 Panobinostat Farydak 20.0 mg/1 Chemotherapy Enzyme Inhibitor HDAC Oral Feb. 23, 2015 Dec. 31, 2022 No Longer Used
30698-0201-01 30698-0201 Bromocriptine Mesylate Parlodel 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 28, 2014 In Use
30698-0201-30 30698-0201 Bromocriptine Mesylate Parlodel 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 28, 2014 In Use
30698-0202-01 30698-0202 Bromocriptine Mesylate Parlodel 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 28, 2014 In Use
30698-0202-30 30698-0202 Bromocriptine Mesylate Parlodel 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 28, 2014 In Use
46708-0565-30 46708-0565 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
46708-0565-90 46708-0565 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
46708-0566-30 46708-0566 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
46708-0566-90 46708-0566 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
46708-0567-30 46708-0567 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
46708-0567-90 46708-0567 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
58181-3040-05 58181-3040 Lomustine Gleostine 10.0 mg/1 Chemotherapy Alkylating Agent Nitrosourea Oral Aug. 18, 2014 In Use
58181-3041-05 58181-3041 Lomustine Gleostine 40.0 mg/1 Chemotherapy Alkylating Agent Nitrosourea Oral Aug. 18, 2014 In Use
58181-3042-05 58181-3042 Lomustine Gleostine 100.0 mg/1 Chemotherapy Alkylating Agent Nitrosourea Oral Aug. 18, 2014 In Use
59923-0604-02 59923-0604 Fludarabine Phosphate Fludarabine Phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Dec. 31, 2019 In Use
59923-0703-05 59923-0703 temozolomide TEMOZOLOMIDE 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jan. 25, 2019 In Use
59923-0704-14 59923-0704 temozolomide TEMOZOLOMIDE 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jan. 25, 2019 In Use
59923-0705-05 59923-0705 temozolomide TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jan. 25, 2019 In Use
59923-0706-14 59923-0706 temozolomide TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jan. 25, 2019 In Use

Found 10,000 results in 6 milliseconds — Export these results